Windtree Enter Asset Purchase Agreement With Varian Biopharmaceuticals To Acquire Certain Of Its Assets, Including A Proprietary Atypical Protein Kinase C Iota Inhibitor
Windtree Enter Asset Purchase Agreement With Varian Biopharmaceuticals To Acquire Certain Of Its Assets, Including A Proprietary Atypical Protein Kinase C Iota Inhibitor
Windtree與瓦里安生物製藥公司簽訂資產購買協議，以收購其部分資產，包括專有的非典型蛋白激酶C Iota抑制劑
The Company also completed a $1.5 million convertible note bridge financing. With successful development, the Company would pay up to $2.3 million in milestone payments upon the achievement of certain regulatory and clinical development milestones relating to the acquired assets with the Company having the option to pay such milestone payments either in cash or the Company's common stock.
該公司還完成了150萬美元的可轉換票據過渡融資。成功開發後，公司將在實現與收購資產相關的某些監管和臨床開發里程碑後支付高達230萬美元的里程碑式付款，公司可以選擇以現金或公司普通股支付此類里程碑式的款項。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。